CTRI/2021/08/035482尚未招募4 期
Open label randomised study to compare etomidate and propof ol for general anaesthesia in ambulatory anal and perianal surgeries
Panjab institute of medical sciences Jalandhar0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •This open label randomized study will be conducted at Punjab Institute of Medical Sciences often approval of Institutional Ethical committee and registration of clinical trial on 60 adult patients of age group (18-60yrs), ASA grade I & II posted for anal and perianal surgeries of 25-30 minutes duration.
- •Exclusion criteria:
排除标准
- •History of respiratory disease
- •History of renal and liver disorder.
- •History of haemodynamic instability
- •History of allergy to propofol or etomidate
研究者
相似试验
尚未招募
不适用
Comparative study of Etomidate and Propofol for anesthesia in patients with Cervical compression and deranged Heart rate variabilityCTRI/2021/01/030207Dr Geetha
进行中（未招募）
1 期
An open-label study to compare the effectiveness of FF/UMEC/VI using the Connected Inhaler System with FP/SAL plus tiotropium in participants with inadequately controlled asthmaEUCTR2017-001532-19-NLGlaxoSmithKline Research & Development Ltd1,006
进行中（未招募）
不适用
A randomised, open label study to compare the efficacy and safety of a dry powder formulation of inhaled Colistimethate Sodium and nebulised TNSFI (Tobramycin nebuliser solution for inhalation, TOBI®) in cystic fibrosis patients with pseudomonas aeruginosa lung infectioPseudomonas aeruginosa (PA) infection in patients with cystic fibrosis.EUCTR2004-003675-36-BEForest Laboratories UK Ltd360
进行中（未招募）
不适用
A randomised, open label study to compare the efficacy and safety of a dry powder formulation of inhaled Colistimethate Sodium and nebulised TNSFI (Tobramycin nebuliser solution for inhalation, TOBI®) in cystic fibrosis patients with pseudomonas aeruginosa lung infectioEUCTR2004-003675-36-DKForest Laboratories UK Ltd360
进行中（未招募）
不适用
A randomised, open label study to compare the efficacy and safety of a dry powder formulation of inhaled Colistimethate Sodium and nebulised TNSFI (Tobramycin nebuliser solution for inhalation, TOBI®) in cystic fibrosis patients with pseudomonas aeruginosa lung infectioPseudomonas aeruginosa (PA) infection in patients with cystic fibrosis.EUCTR2004-003675-36-ATForest Laboratories UK Ltd360